Pluvicto, a prostate cancer drug, has gained expanded approval that triples the number of patients with metastatic disease ...

Adding pembrolizumab to docetaxel did not significantly improve outcomes in previously treated patients with mCRPC.

The radiopharmaceutical lutetium 177 can be used after radium 223 to treat metastatic castration-resistant prostate cancer.

The radioligand agent is now approved for use before chemotherapy in patients who have been treated with an androgen receptor ...

For many years, mCRPC was considered to confer a terminal prognosis, with a median survival of 12 months from development of castrate resistance. [2] However, the advent of several new agents has ...

The FDA approved several therapies in oncology in the month of March 2025. These drugs included treatments for ...

Men with metastatic castration-resistant prostate cancer (mCRPC) lived 19-20 months whether they received docetaxel plus pembrolizumab (Keytruda) or placebo. The addition of pembrolizumab did not ...

The antibody-drug conjugate FOR46 showed the strong potential of using CD46 as a new therapeutic target in metastatic ...

Xencor's stock drops 65%, hitting all-time lows. Focus shifts to autoimmune research, but no near-term catalysts. Read why ...

The FDA has expanded the approval for Pluvicto (lutetium Lu 177 vipivotide tetraxetan) to include patients with PSMA-positive mCRPC who have been treated with ARPI therapy and can delay chemotherapy.

The randomised trial uses a companion lipid biomarker test, PCPro, to identify mCRPC patients with a poor prognosis who may benefit from the combination. In the trial, 200 eligible subjects will ...

reduced the fracture rate in the EORTC 1333/PEACE-3 trial comparing radium-223 plus enzalutamide versus enzalutamide alone in patients with metastatic castration-resistant prostate cancer (mCRPC ...